Very important pharmacogene summary
- 1 March 2011
- journal article
- pharmgkb summary
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 21 (3), 152-161
- https://doi.org/10.1097/fpc.0b013e3283385a1c
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1): I. Preclinical aspectsDrug Discovery Today, 2007
- A haplotype map of the human genomeNature, 2005
- Characterization of the humanMDR1 geneThe AAPS Journal, 2005
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- MDR1 haplotypes derived from exons 21 and 26 do not affect the steady‐state pharmacokinetics of tacrolimus in renal transplant patientsBritish Journal of Clinical Pharmacology, 2004
- A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell CarcinomaClinical Cancer Research, 2004
- MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel DiseaseAmerican Journal of Human Genetics, 2003
- Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Regulation of volume‐activated chloride channels by P‐glycoprotein: phosphorylation has the final say!Journal Of Physiology-London, 2000
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999